Diabetic Macular Edema (DME)
Conditions
Keywords
intravitreal bevacizumab, suprachoroidal triamcinolone, diabetic macular edema
Brief summary
Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema
Detailed description
Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema. Those patients who had glaucoma history or IOP above 21 mm of Hg, Phakic, corneal opacity, vitreous hemorrhage, proliferative diabetic retinopathy, already received anti-VEGF injections, history of pan-retinal photocoagulation for proliferative diabetic retinopathy.
Interventions
Intravitreal bevacizumab alone
DRUGintravitreal bevacizumab and suprachoroidal triamcinolone acetonide
Combination of Intravitreal bevacizumab and suprachoroidal triamcinolone acetonide
Sponsors
Khyber Teaching Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
32 Years to 78 Years
Healthy volunteers
No
Inclusion criteria
* Patients with center involving diabetic macular edema on optical coherence tomography
Exclusion criteria
* Raised intraocular pressure * History of glaucoma * Corneal opacity * Vitreous hemorrhage * Proliferative diabetic retinopathy * Anti-VEGF injections in last 3 months * History of pan-retinal photocoagulation * Contraindications for anti-VEGF
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Central macular thickness | 3 months | Effect of both treatment on central macular thickness measure on optical coherence tomography |
| Visual Acuity | 3 months | Improvement in best corrected visual acuity |
Countries
Pakistan
Outcome results
None listed